Connors M, Kovacs J A, Krevat S, Gea-Banacloche J C, Sneller M C, Flanigan M, Metcalf J A, Walker R E, Falloon J, Baseler M, Feuerstein I, Masur H, Lane H C
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-1876, USA.
Nat Med. 1997 May;3(5):533-40. doi: 10.1038/nm0597-533.
Changes in CD4+ T-cell surface marker phenotype and antigen receptor (TCR) repertoire were examined during the course of HIV infection and following therapy. A preferential decline in naive CD4+ T cells was noted as disease progressed. Following protease inhibitor therapy, naive CD4+ T cells increased only if they were present before initiation of therapy. Disruptions of the CD4+ TCR repertoire were most prevalent in patients with the lowest CD4+ T-cell counts. Antiviral or IL-12 therapy-induced increases in CD4+ T-cell counts led to only minor changes in previously disrupted repertoires. Thus, CD4+ T-cell death mediated by HIV-1 infection may result in a preferential decline in the number of naive CD4+ T cells and disruptions of the CD4+ T-cell repertoire that are not immediately corrected by antiviral or immune-based therapies.
在HIV感染过程中和治疗后,对CD4 + T细胞表面标志物表型和抗原受体(TCR)库的变化进行了检查。随着疾病进展,观察到初始CD4 + T细胞出现优先下降。蛋白酶抑制剂治疗后,仅当初始CD4 + T细胞在治疗开始前就已存在时才会增加。CD4 + TCR库的破坏在CD4 + T细胞计数最低的患者中最为普遍。抗病毒或IL - 12治疗诱导的CD4 + T细胞计数增加仅导致先前破坏的库中出现微小变化。因此,由HIV - 1感染介导的CD4 + T细胞死亡可能导致初始CD4 + T细胞数量优先下降以及CD4 + T细胞库的破坏,而抗病毒或基于免疫的治疗并不能立即纠正这些破坏。